Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986263 in Advanced Hepatic Fibrosis After HCV Cure
NCT03420768Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2018
- Primary completion
- Dec 2018
- Modality
- Antisense DNA, Lipid-based Nanoparticles, Conjugated siRNA
- Countries
- 1
01
Overview
A Phase 2 trial of ND-L02-s0201 in hepatic fibrosis, sponsored by Bristol Myers Squibb. Started Feb 2018; status: completed.
02
Drugs
ND-L02-s0201
03
Conditions
hepatic fibrosis
Beyond the preview
Go deeper on NCT03420768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03420768.